Section II. (Amendments to the Claims)

Please amend claims 9, 15, 16, 19 and 23, as set out below in the listing of claims 1-23 of the application.

1. (Original) A vector for preparing a vaccine which contains one or more than two gene among pgs B, pgs C and pgs A encoding poly-χ-glutamate synthetase complex and an antigen protein gene of human papilloma virus.

2. (Original) The vector for preparing a vaccine according to claim 1, in which said antigen protein gene is one or more than two genes selected from a group comprising capsid HPV L1 and HPV L2 of human papilloma virus.

3. (Original) The vector for preparing a vaccine according to claim 1, in which said antigen protein gene is one or more than two genes selected from a group comprising HPV E6 and HPV E7 antigen protein associated with a tumor induction.

4. (Currently amended) The vector for preparing a vaccine according to claim 1, in which pgs A gene encoding said poly-χ-glutamate synthetase complex is contained.

5. (Original) A Gram negative microbe which is transformed with the vector for preparing a vaccine of claim 1.

6. (Original) The microbe according to claim 5, in which said microbe is selected from a group comprising Escherichia coli, Salmonella typhi, Salmonella typimurium, Mycobacterium bovis, and Shigella.

7. (Original) A Gram positive microbe which is transformed with the vector for preparing a vaccine of claim 1.

8. (Original) The microbe according to claim 7, in which said microbe is selected from a group comprising Bacillus, Lactobacillus, Lactococcus, Staphylococcus, Lysteria, Monocytogenesis, and Streptococcus.

9. (Currently amended) A vaccine for treating or preventing mucosal tumor, which contains as an effective component, ~~the~~ microbes ~~of claim 5 and claim 7~~ transformed with the vector of claim 1,

expressing an antigen protein onto a cell surface, crude antigen proteins extract from said microbes or antigen proteins purified from said microbes.

10. (Original) The vaccine for treating or preventing mucosal tumor according to claim 9, which can be administered orally or be edible.

11. (Original) The vaccine for treating or preventing mucus tumor according to claim 9, which can be injected subcutaneously or peritoneally.

12. (Original) The vaccine for treating or preventing mucosal tumor according to claim 9, which can be sprayed to the nasal cavity.

13. (Original) The vector for preparing a vaccine according to claim 1, which has the genetic map as illustrated in Fig. 1 and is named as pHCE2LB: pgsA-HPV L1.

14. (Original) The vector for preparing a vaccine according to claim 1, which has the genetic map as illustrated in Fig. 5 and is named as pHCE2LB: pgsBCA- HPV E7.

15. (Original) A microbe which is transformed with ~~the~~ a vector ~~for preparing a vaccine of claim 13 or claim 14~~ selected from the group consisting of pHCE2LB: pgsA-HPV L1 and pHCE2LB: pgsBCA- HPV E7.

16. (Currently amended) The microbe according to claim 15, in which Lactobacillus or Salmonella ~~Is~~ is used as a host cell.

17. (Original) The Escherichia coli transformant which is transformed with the vector of claim 13 (accession number: KCTC 10349 BP)

18. (Original) The Escherichia coli transformant which is transformed with the vector of claim 13 (accession number: KCTC 10520 BP)

19. (Currently amended) A vaccine for treating or preventing mucosal tumor which includes as an effective component, the ~~microbes~~ microbe of claim 16 expressing an antigen protein onto a cell surface, crude antigen proteins extract from said ~~microbes~~ microbe or antigen proteins purified from said ~~microbes~~ microbe.

20. (Original) The vaccine for treating or preventing mucosal tumor according to claim 19, which can be administered orally or be edible.

21. (Original) The vaccine for treating or preventing mucosal tumor according to claim 19, which can be injected subcutaneously or peritoneally.

22. (Original) The vaccine for treating or preventing mucosal tumor according to claim 19, which can be sprayed to the nasal cavity.

23. (Currently amended) A washing solution for a genital organ, which includes as an effective component, the ~~microbes~~ microbe of claim 16 expressing an antigen protein onto a cell surface, crude antigen protein extract from said ~~microbes~~ microbe or antigen proteins purified from said ~~microbes~~ microbe.